Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

JAKAVI DIN 02434814

Status: Marketed
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: RUXOLITINIB (RUXOLITINIB PHOSPHATE)
Available to quote

Health Canada record

Active ingredient(s)RUXOLITINIB (RUXOLITINIB PHOSPHATE) 10 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCL01EJ01 RUXOLITINIB
Original market date15-Apr-2015
Current status date15-Apr-2015
SourceHealth Canada DPD

Establishment licence of the holder

Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing RUXOLITINIB (RUXOLITINIB PHOSPHATE)

DINProductCompanyFormStrengthStatus
02388006JAKAVINOVARTIS PHARMACEUTICALS CANADA INCTabletRUXOLITINIB (RUXOLITINIB PHOSPHATE) 5 MGMarketed
02388014JAKAVINOVARTIS PHARMACEUTICALS CANADA INCTabletRUXOLITINIB (RUXOLITINIB PHOSPHATE) 15 MGMarketed
02388022JAKAVINOVARTIS PHARMACEUTICALS CANADA INCTabletRUXOLITINIB (RUXOLITINIB PHOSPHATE) 20 MGMarketed
02552434OPZELURAINCYTE CORPORATIONCreamRUXOLITINIB (RUXOLITINIB PHOSPHATE) 1.5 %Marketed

Notices of Compliance

NOCDateSubmissionReason
163962014-12-02Supplement to a New Drug Submission (SNDS)NEW STRENGTH
Request a quote for JAKAVI

How to read a Canadian DIN record